Colchicine

SKU: orb1310726

Description

Colchicine is a potent natural alkaloid that inhibits microtubule polymerization (IC50 = 3 nM) and acts as a competitive glycine receptor antagonist. It is widely used in research for its anti-inflammatory and immunosuppressive properties, applied in studies of gout, rheumatoid arthritis, Alzheimer's disease models, and NLRP3 inflammasome-related pathologies in both cellular and animal studies.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 64-86-8
• MW: 399.44
• Purity: 99.96% (May vary between batches)
• Formula: C₂₂H₂₅NO₆
• SMILES: COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
• Target: Microtubule Associated,Apoptosis,Autophagy
• Solubility: H2O:1.33 mg/mL (3.33 mM);DMSO:257.5 mg/mL (644.65 mM)

Bioactivity

• Target IC50:
  A10 cells:0.03 μM (EC50)|Microtubule:3 nM|786-O cells:0.022 μM
• In Vivo:
  METHODS: To investigate the antitumor activity, Colchicine (0.1 mg/kg) was orally administered to BALB/c-nu mice bearing the human pharyngeal cancer tumor FaDu every two days for fourteen days. RESULTS: Colchicine was effective in inhibiting tumor growth in a hypopharyngeal cancer model nude mouse without serious complications. METHODS: To investigate the effect of anti-Fas antibody-induced lethality, Colchicine (2 mg/kg) was injected intraperitoneally into C57BL/6 mice, followed by Jo2 antibody (10 μg) 24 h later. RESULTS: All mice treated with Colchicine survived the lethal attack.Colchicine reduced the susceptibility of mice to the lethal effect of Jo2 against Fas antibody.
• In Vitro:
  METHODS: Human pharyngeal carcinoma cells FaDu and SNU1041 were treated with Colchicine (0.0-1 μM) for 24-72 h. Cell viability was measured by XTT assay. RESULTS: Colchicine treatment was cytotoxic to both FaDu and SNU1041 cell lines in a dose- and time-dependent manner. METHODS: Chorionic villous cells AFCs and amniotic fluid cells CVCs were treated with Colchicine (0.15 μg/mL) for 3-24 h. Apoptosis was detected by Flow Cytometry. RESULTS: Colchicine induced a significant increase in the proportion of annexin V and PI double positive cells.
• Animal Research:
  a C57BL/6 background are used. To examine the effects of Colchicine on NSAID-induced small intestinal injury, vehicle or Colchicine (1 or 3 mg/kg) is administered orally 30 min prior to indomethacin administration. Mice received intraperitoneal injections of sterilized phosphate buffered saline or mouse recombinant IL-1β (0.1 μg/kg) 3 h after indomethacin treatment. Vehicle or Colchicine (1 or 3 mg/kg) is also administered to NLRP3 / mice before indomethacin administration. The lesion index is evaluated 24 h after indomethacin administration and examined mRNA and protein expression of inflammasome components 6 h after indomethacin administration.

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

microtubule, MicrotubuleAssociated, Microtubule/Tubulin, Microtubule Associated, inhibit, Inhibitor, Apoptosis, Autophagy, Colchicine, Colchineos, Colchisol, Colcin

Compound Identifiers

PubChem CID

2833